阿波利波蛋白D作为神经精神疾病潜在生物标志物
Eva Del Valle1,2,3, Nuria Rubio-Sardón1,2,3, Carlota Menéndez-Pérez1,2,3
1Department of Morphology and Cell Biology, University of Oviedo, 33006 Oviedo, Spain.
International journal of molecular sciences
|November 14, 2023
概括
阿波蛋白D (Apo D) 显示出作为神经精神疾病 (ND) 的生物标志物的潜力. 需要进一步的研究来确认Apo D水平是否可以表明ND检测和进展.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 精神病学是一个精神病学.
背景情况:
- 神经精神疾病 (NDs) 是复杂的,增加全球健康问题.
- 由于异质的症状和原因,诊断是具有挑战性的.
- 新型生物标志物对于早期检测和有效治疗至关重要.
研究的目的:
- 审查阿波利波蛋白D (Apo D) 作为NDs生物标志物的临床潜力.
- 评估Apo D水平是否可以表明ND检测和进展.
- 提供关于Apo D在神经精神疾病中的作用的最新视角.
主要方法:
- 对Apo D和NDs研究的文献综述.
- 与衰老和神经病理学有关的Apo D表达的分析.
- 检查Apo D在神经保护,氧化应激和炎症中的作用.
主要成果:
- Apo D参与脂质代谢和神经保护.
- 增加Apo D表达与衰老和神经病理过程有关.
- 在精神分裂症和双相情感障碍等疾病中,在脑组织和体液中观察到改变的Apo D水平.
结论:
- Apo D 是一个有前途的候选生物标志物用于NDs.
- 需要进一步的研究来验证Apo D在检测和监测ND的实用性.
- 了解Apo D的作用可能会导致新的诊断和治疗策略.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
10:51Consensus Brain-derived Protein, Extraction Protocol for the Study of Human and Murine Brain Proteome Using Both 2D-DIGE and Mini 2DE Immunoblotting
Published on: April 10, 2014
16.1K
相关概念视频
01:26Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
01:22Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197